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Abstract: The use of 3D printing techniques to control drug release has flourished in the past decade,
although there is no generic solution that can be applied to the full range of drugs or solid dosage
forms. The present study provides a new concept, using the 3D printing technique to print a coating
system in the form of shells with various designs to control/modify drug release in immediate-release
tablets. A coating system of cellulose acetate in the form of an encapsulating shell was printed
through extrusion-based 3D printing technology, where an immediate-release propranolol HCl tablet
was placed inside to achieve a sustained drug release profile. The current work investigated the
influence of shell composition by using different excipients and also by exploring the impact of shell
size on the drug release from the encapsulated tablet. Three-dimensional printed shells with different
ratios of rate-controlling polymer (cellulose acetate) and pore-forming agent (D-mannitol) showed
the ability to control the amount and the rate of propranolol HCl release from the encapsulated
tablet model. The shell-print approach also showed that space/gap available for drug dissolution
between the shell wall and the enclosed tablet significantly influenced the release of propranolol
HCl. The modified release profile of propranolol HCl achieved through enclosing the tablet in a
3D printed controlled-release shell followed Korsmeyer–Peppas kinetics with non-Fickian diffusion.
This approach could be utilized to tailor the release profile of a Biopharmaceutics Classification
System (BCS) class I drug tablet (characterized by high solubility and high permeability) to improve
patient compliance and promote personalized medicine.
Keywords: 3D printing technology; solid dosage forms; controlled release; propranolol HCl; cellulose
acetate; release kinetic; personalized medicine
1. Introduction
The concept of a one-size-fits-all dosage form is challenging and difficult to achieve due to the
high individual variability related to genetics, ethnicity, gender, age, and patient weight [1]. In real
practice, some patients will be exposed to either high or low doses, with exposure to unwanted side
effects. The concept of personalized medicine has grown dramatically in popularity in recent years,
as dose adjustments can be made according to the pharmacokinetic and pharmacogenetic profile of the
patient [2].
Three-dimensional printing technologies have been exploited for personalized drug delivery [3].
To achieve the goal of personalized medicine, the 3D printing technique was utilized to design,
for example, a five-in-one dose combination polypill with defined immediate and extended-release
profiles [4], a multi-layered polypill as a platform for multi-drug therapy production [5], tablets with
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fully customizable release profiles [6], and dosage forms to deliver tailored individualized precision
dosing of anti-coagulant [7]. This technology can be used to fabricate pharmaceutical formulations
in different sizes and shapes using a variety of materials with customized drug concentrations
and release profiles that cannot be produced using conventional mass production methods in the
pharmaceutical industry [8]. Different types of 3D printers using inkjet printing [9], stereolithography
(SLA) [10], selective laser sintering (SLS) [11], fused deposition modeling [12], and extrusion-based
pressure-assisted micro syringes [13] have been used to develop various types of drug delivery systems
and novel devices such as transdermal patches [14], intrauterine and sub-cutaneous devices [15,16],
and biodegradable implants [17]. Recently, Dumpa et al. developed a gastro-retentive floating
pulsatile drug delivery system where the investigator enclosed a theophylline tablet prepared by direct
compression into a floating shell, exploiting the 3D printing technique (hot-melt extrusion-paired
fused-deposition modeling) for the treatment of chronic asthma [18].
Here, we propose a potential application of 3D printing technology to modify the release profile
of an immediate-release tablet. An extrusion-based printing method was used in this work as it
allows for a broad selection of suitable polymers and excipients, and also allows for printing with
different polymer and excipients ratios; therefore, modified release profiles could be easily achieved by
printing solid dosage forms of specific desirability, exploiting the computer-aided design (CAD) process.
The current study aims to develop an encapsulating system (shell) to provide a controlled-release
coating layer over an immediate-release tablet (using propranolol HCl (Indicardin®, 40 mg tablet)
as a model) to achieve a sustained release profile of the drug. Propranolol HCl is a beta-blocker
commercially available in different dosage forms, including capsules, tablets, and oral solutions.
Propranolol HCl has a short elimination half-life (3 h). Therefore, frequent dosing (3–4 times a day)
is prescribed to achieve optimal therapeutic efficacy. The development of a drug delivery system to
deliver propranolol HCl at a controlled rate is required to minimize the dosing frequency and reduce
fluctuations in systemic drug concentrations [19]. Based on the Biopharmaceutics Classification System
(BCS), propranolol HCl is a class I drug (high soluble and high permeable), with a dose number (Do)
of 0.0025. These characteristics of propranolol HCl make it an excellent candidate for the development
of modified-release dosage products [20]. The tablet was placed inside a 3D printed controlled-release
shell to observe the change in dissolution profile and release kinetics of propranolol HCl.
2. Materials and Methods
2.1. Materials
Propranolol HCl (Indicardin®, 40 mg) was supplied by the Najran University Hospital pharmacy,
Najran, Saudi Arabia. Cellulose acetate, D-mannitol, and polyethylene glycol (PEG) 6000 were
purchased from Sigma-Aldrich (Gillingham, UK). Ethanol, acetone, dimethyl sulfoxide (DMSO) were
purchased from UFC Biotech (Riyadh, KSA), and all other reagents were of analytical grade.
2.2. Preparation of Material for Extrusion-Based 3D Printing of Controlled-Release Tablet Shells
A hydrophobic polymer was selected to prepare 3D printed controlled-release shells in order to
modify the release of enclosed immediate release tablet. Along with the polymer, a suitable filler (as a
pore-forming agent to control the porosity) and a plasticizer (to improve shell plasticity) were added to
the shell composition. All the optimized materials (hydrophobic polymer, filler, and plasticizer) in
varying compositions were mixed properly and pulverized using a mortar and pestle. A solvent system
was optimized to convert the selected materials into a paste of extrudable consistency. The selected
materials were mixed with a fixed volume of the solvent system to transform into a homogenous paste
with continuous stirring.
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2.3. Process Optimization for 3D Printing of Controlled Release Tablet Shells
Material for 3D printing was selected for the extrusion printing of controlled-release shells to
encapsulate the tablet with an immediate release profile. Material extrusion requires optimization of
various printing parameters in order to obtain stable deposition and a well-defined geometry of the
controlled-release shells. These optimization parameters include consistency of the extruding paste,
printing pressure, nozzle diameter (printer tip), and printing speed.
2.4. Design of 3D Printed Controlled-Release Tablet Shells
The geometry of controlled-release shell exploiting CAD was designed with respect to the
dimensions of the selected tablet model. The design of the controlled-release shell was arranged in two
parts: a shell body and a cap. The body of the controlled-release tablet shell was printed first and then
the tablet was placed inside it, with subsequent printing of the cap of the shell. Different dimensions of
controlled-release shells were printed to customize the drug release profile.
2.5. Evaluation of Propranolol HCl Tablet
2.5.1. Assay/Drug Content
An assay of the propranolol HCl tablet was performed as per the method described in the British
Pharmacopoeia to determine the drug content. Twenty tablets were accurately weighed and crushed
into a powder form. Propranolol HCl (20 mg) was dissolved in 20 mL of distilled water and shaken
for 10 min. Then, 50 mL of methanol was added to this and shaken for another 10 min. A sufficient
volume of methanol (30 mL) was then added to make the volume up to 100 mL, and then filtered.
Finally, 10 mL of this filtrate was diluted in 50 mL of methanol and the resulting solution was used to
measure the absorbance at 290 nm. The content of propranolol HCl was then calculated as described
in the Pharmacopoeia [21]. The content of propranolol HCl tablet was found to be 39.78 ± 1.14 mg,
with a percentage content of 99.45% of the tablet dose.
2.5.2. In Vitro Dissolution Study
A dissolution study was carried out for the immediate-release tablet of propranolol hydrochloride
using a United States Pharmacopeia (USP) type 1 dissolution apparatus in 0.1N HCl at 100 rpm.
The 5-mL samples were withdrawn at regular time intervals (5, 10, 15, 20, 30, and 45 min) to quantify the
drug release. The withdrawn sample was filtered through a syringe filter and spectrophotometrically
analyzed to estimate the concentration of propranolol hydrochloride in release media at the wavelength
of 290 nm [22].
2.6. Encapsulation of Propranolol HCl Tablets
The formulated paste was placed in an extruding syringe and loaded into the 3D printer (Biobot 1).
A 600-µm nozzle tip was fixed to the extruding syringe. The printing pressure was set between
40 and 60 psi based on the paste composition and consistency. The G-code files were uploaded to
the printer software and the files were run to conduct the printing process. Firstly, the body of the
controlled-release shell was printed; then, the propranolol HCl tablet was placed inside the printed
shell. The cap of the controlled-release shell was then printed over the top of the body to close the
controlled-release shell. The total printing time was approximately 4–6 min for each print. The printing
speed was 4 mm/s and was kept constant. After printing, the 3D printed tablets were placed in a
vacuum dryer overnight to complete the drying process.
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2.7. Characterization of Printed Controlled-Release Shell
2.7.1. Fourier-Transform Infrared Spectroscopy (FTIR)
FTIR was performed to detect drug–excipient interactions during the 3D printing process. Infrared
spectra were obtained for the physical mixture of ingredients and the 3D printed controlled-release shell
using an FTIR spectrometer (Agilent Cary630 FTIR). A small amount of powdered excipient mixture
used in the shell preparation was analyzed at wavenumbers between 400 and 4000 cm−1. The results
from the excipient physical mixture were compared to a sample of the 3D printed controlled-release
shell to assess any drug–excipient interactions during the 3D printing process [23].
2.7.2. Differential Scanning Calorimetry (DSC)
DSC analysis was carried out for the physical mixture of excipients (cellulose acetate, D-mannitol,
and PEG 6000) and the 3D printed controlled-release shell using a TA DSC25 Instrument. The physical
mixture of the material and the 3D printed controlled-release shell were powdered and sieved.
An accurately weighed amount of sample (5 mg) was placed in a Tzero aluminium pan and sealed
completely. The nitrogen flow rate used for the analysis was 50 mL/min and the heating rate was set at
10 ◦C/min using an empty Tzero aluminium pan as a reference [24].
2.8. In-Vitro Dissolution Study
2.8.1. Drug Release Profile
In vitro drug dissolution studies were performed for the 3D printed tablets of different compositions
and sizes using USP type 1 dissolution apparatus as per the monograph for propranolol HCl at 100 rpm
using 900 mL of phosphate buffer (pH 6.8) as the dissolution medium at a temperature of 37 ± 0.5 ◦C.
The amount of sample withdrawn was 5 mL at the time points of 5, 10, 15, 30, 60, 120, 240, 360, 480,
600, and 720 min. The withdrawn sample was filtered through a syringe filter and analyzed using a UV
spectrophotometer at 290 nm. The dissolution studies were performed in triplicate and the cumulative
percentage of drug release with respect to time was determined [25,26].
2.8.2. Drug Release Kinetics
The drug release kinetics which showed the mechanism of overall release of drug from the
developed formulations were subjected to quantitative and qualitative changes in formulation designs
considered as rational to understand the release mechanism. The propranolol HCl release kinetics
from the encapsulated tablet in the printed shells of different composition and sizes were determined
by using the best-fit model [27].
3. Results and Discussion
3.1. Preparation of Material for 3D Printing of Controlled-Release Tablet Shells
Pharmaceutical product development exploiting the 3D printing technique requires specific
consideration of material choice in accordance with the method used for printing. For example, the fused
deposition modeling (FDM) method requires the use of thermoplastic materials extruded at high
temperatures. The current investigation involved the use of a pressure-assisted microsyringe (PAM) that
requires materials to be extruded at room temperature in a semi-solid state, which consequently dry after
extrusion from the printer.
For the shell composition, different hydrophobic polymers were investigated in order to modify
the drug release of the tablet enclosed inside the core of the shell. The material was optimized
for extrusion through the 3D printer and explored for its ability to build a layer-by-layer design of
controlled/sustained-release shells. The selection of the polymers and all other excipients/chemicals
exploited in this investigation was based on well-reported use in literature for the preparation of tablet
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shells. These excipients have been well exploited using the PAM-based 3D printing technique for
pharmaceutical product development [4,24,28,29] and/or the formulation of controlled/sustained-release
tablets [30,31]. The polymers investigated to assess extrusion ability through the 3D printer included
ethyl cellulose, hydroxyl propyl methylcellulose (HPMC), polyvinylpyrrolidone (PVP), and cellulose
acetate. These polymers were dissolved in different types of solvent and tested to form a paste
of desirable consistency that should be suitable for 3D printing. The solvents investigated for the
formation of paste with good extrusion consistency included methanol, ethanol, isopropyl alcohol,
dichloromethane, dimethyl sulfoxide, and acetone. The optimization of the solvents exploited in the
preparation of a paste with good extrusion consistency should take into consideration the rheology of
the formulated paste and the time required to evaporate the solvent. Solvents should not be highly
evaporative, as this may cause fast drying of the extrusion material at the tip of the nozzle, ultimately
causing a blockage. However, slow evaporation of the solvent may increase the time required for
solidification of the printed layers and ultimately hamper the formation of the layer-by-layer 3D
structure. The extrusion paste should be smooth and homogeneous in order to exhibit good flow
characteristics through the nozzle tip and be free from the occurrence of large particles that may
cause blockage of the nozzle tip during the extrusion process. Among the various polymers assessed
for the preparation of pastes, ethylcellulose, HPMC, and PVP exhibited variable characteristics in
terms of the formed paste, including consistency, rheology, and extrusion behaviour. During the
deposition observation, these materials showed high wettability at the interface with the borosilicate
glass substrate, which prevented the building of a layer-by-layer 3D structure. Based on the physical
properties and rheological behaviour during extrusion, cellulose acetate was found to be a suitable
polymer to print the controlled-release tablet shells. Polyethylene glycol (PEG) is one of the most
efficient plasticizers used in polymer-based pharmaceutical product development as it has a broad
range of molecular weight grades available, is nontoxic in nature, and shows miscibility with a wide
range of pharmaceutical excipients as well as biodegradability [32].
Furthermore, among the different grades of PEG, the higher molecular weight grade provides a
better plasticizing effect [33]; therefore, PEG 6000 was added as a plasticizer to the shell composition.
The amount of solvent plays an essential role in affecting the flow behaviour of the paste. A combination
of solvents was used to prepare the cellulose acetate paste for extrusion-based 3D printing. The use of
a highly evaporative solvent will lead to rapid drying of the paste causing a nozzle blockage, and the
use of a slowly evaporating solvent will increase the ink spreading upon printing and complicate the
formation of well-defined layer-by-layer 3D structures. To overcome this, a combination of solvent
mixture was used to provide the optimum rate of solvent evaporation from the paste after extrusion
through the 3D printer. The miscibility/solubility profile of cellulose acetate in different solvents and
the resulting solution behaviour, along with the extrudability characteristics of the paste through the
3D printer, are shown in Table 1.
The cellulose acetate was dissolved in a combination of acetone, ethanol, and DMSO in the
ratio of 2.5:2.5:1 and optimized as extrusion material for the printing of controlled-release tablet
shells. The DMSO added as co-solvent for cellulose acetate was within the permissible limits and
concentrations safe for use in humans [34,35]. The optimized materials for the shell formation were
composed of cellulose acetate, D-mannitol, and PEG 6000. It was mixed properly and pulverized
using a mortar and pestle. Then, 3.0 g of the blended powder mixture of cellulose acetate, D-mannitol,
and PEG 6000 was taken and mixed with a fixed volume (2.4 mL) of the solvent system (acetone,
ethanol, and DMSO in the ratio of 2.5:2.5:1 v/v) to make a homogenous paste of a semi-solid consistency
with continuous stirring.
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Table 1. Miscibility/solubility profile of cellulose acetate in different solvents and the resulting solution
behaviour, along with extrudability characteristics of the paste through the 3D printer.
Solvent Solubility Solution Behavior and ExtrudabilityThrough the 3D Printer
Water Insoluble Insoluble mass
Water with surfactant (Tween 80) Insoluble Granular mass
Isopropyl alcohol Insoluble Insoluble mass
Ethanol Insoluble Insoluble mass
Dichloromethane Insoluble Insoluble mass
Ethyl acetate Partially soluble Segregated mass
Acetone Soluble Paste extruded rapidly, but tip blockageoccurred due to drying of the paste over time
Acetone/water (1:1 ratio) Insoluble Segregated mass
Acetone/ethanol (1:1 ratio) Insoluble Gummy mass
Acetone/isopropyl alcohol (1:1 ratio) Insoluble Gummy mass
Acetone/propylene glycol (4:1 ratio) Soluble Paste but hindered extrusion
Acetone/isopropyl alcohol (3:2 ratio) Soluble Paste but no continuous extrusion
Acetone/ethanol/ dimethyl sulfoxide
(DMSO) (2.5:2.5:1 ratio) Soluble
Good uniformity and continuously
extrudable paste
3.2. Process Optimization for 3D Printing Controlled-Release Tablet Shells
Among the various 3D printing technologies exploited for pharmaceutical manufacturing,
the extrusion-based 3D printing technique was investigated for printing controlled-release shells of the
encapsulated tablet. The printer explored for the study was a pressure-assisted semi-solid extrusion-based
3D printer (BIOBOT 1). This technique was optimized for various process parameters (such as paste
consistency, nozzle diameter, printing pressure, and speed) in order to print the controlled-release shell
of various configurations. Firstly, the paste was formed, which was well extruded through the printer
nozzle. The cellulose acetate was dissolved in a combination of acetone, ethanol, and DMSO in a ratio of
2.5:2.5:1, along with a suitable filler (D-mannitol) and plasticizer (PEG 6000) in order to print a stable
layer of controlled-release shell wall with the optimum hardness and drying time. The prepared paste
was placed in an extrusion syringe with nozzles of different diameters attached to the syringe for printing.
The nozzle diameter was optimized for printing. The selection of nozzle size was based on the consistency,
flowability, and particle size of the paste. Tapered nozzles with inner tip diameters of 400–600 µm were
optimized for printing the controlled-release shells. The printing pressure and printing speed were
optimized based on the consistency of the paste. The printing pressure influences the flow behaviour of
the paste through the nozzle and relies on the composition of the paste. The printing pressure was varied
based on the amount of filler added to the composition of extruding paste; 40–60 psi was found to be the
optimum pressure for the printing of controlled-release shells. Similarly, the printing speed of 4 mm/s
was found to be optimum for printing controlled-release shells. All the printing parameters were kept
constant throughout the printing process; the optimization results are summarized in Table 2.
3.3. Design of 3D Printed Controlled-Release Tablet Shells
The empty shell shape was designed to be round, similar to the shape of the tablet chosen for
the study. The size of the selected tablet was 8 mm in diameter and 2.6 mm in thickness. Controlled
release shells of three different sizes (i.e., fixed, medium, and large) were designed to demonstrate
the influence of the gap/space between the shell wall and the enclosed tablet on the dissolution time
and drug release behaviour. The optimized design for printing the tablet shells was developed as a
stereolithography (STL) file and ultimately sliced through a Repetier-Host to create G-code to print the
controlled-release shell for the tablet (illustrated in Figure 1a).
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Table 2. Optimization for the extrusion-based 3D printing process for printing controlled-release
tablet shells.
Process Parameters Value Outcome/Observation
Nozzle size (µm)
200–400 µm No extrusion
400–600 µm Good extrusion with an optimum layer thickness
600–800 µm Very rapid extrusion with an increased layer thickness
Extrusion pressure (psi)
20–40 psi No extrusion
40–60 psi Good extrusion with an optimum layer thickness
60–80 psi Very rapid extrusion with an increased layer thickness
Printing speed (mm/s)
2 mm/s Slow printing
4 mm/s Optimum printing
6 mm/s Rapid printing, sagging due to wetting
Nozzle shape Blunt tip Tip blockage and hindered extrusion
Tapered tip Smooth and continuous extrusion
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3.4. Printing of Controlled-Release Shells to Enclose Propranolol Hcl Tablets
After the optimization of process parameters for 3D printing of the controlled-release shell,
cellulose acetate along with D-mannitol and PEG 6000 were converted into a paste by dissolving them
in a combination of acetone, ethanol, and DMSO at a ratio of 2.5:2.5:1. The paste was placed into the
extruding syringe immediately to avoid unnecessary loss of solvent that could cause drying of paste
and influence its consistency. During the filling of paste into extruding syringe, care should be taken to
avoid air bubble entrapment as its presence may influence the relaxation behavior of the paste. The air
bubbles were minimized by transferring the paste from an initially filled syringe to another syringe
with a seal placed near the barrel tip by using a syringe connector. The printing was done on a glass
substrate. Once the body of the shell was printed, the marketed tablet was placed inside the shell
with the use of tweezers, and then the cap was printed over the top of the enclosed tablet. The design
geometry of the cap and base was identical to provide a uniform and controlled/sustained release of
propranolol HCl from the developed formulation system. The first layer of the cap design was a mesh
pattern to help the tablet remain intact in the center of the shell, whereas the second layer of the cap
was printed over the first layer in a spiral pattern (illustrated in Figure 1b). This printed formulation
system enclosing the tablet was then tested to provide a proof of concept for the 3D printing technique
used to modify the drug release profile of an immediate-release tablet.
3.5. Characterization of 3D Printed Controlled-Release Shells Enclosing the Immediate-Release Tablets
FTIR and DSC analysis were performed in order to determine the potential impact of various
unit operations such as grinding, mixing, solvent addition, paste formation, and drying involved
during the 3D printing process on the material’s behaviour. Furthermore, possible interactions between
the excipients during formulation development were also assessed. The DSC thermogram of the
physical mixture containing PEG 6000, D-mannitol, and cellulose acetate exhibited endothermal peaks
(melting point) at 61.22 ◦C, 168.94 ◦C, and 321.13 ◦C, respectively, while the 3D printed shell showed
no significant changes in the endothermic peaks compared to the excipients used in its formulation
(Figure 2a). This reveals that there were no significant interactions between formulation excipients
during the printing process. Similarly, the FTIR spectra of the physical mixture of the materials
(PEG 6000, D-mannitol, and cellulose acetate) and the 3D printed shell did not exhibit any significant
shift in the position of the characteristic peak (Figure 2b). The FTIR and DSC results indicate that there
were no significant interactions between formulation excipients during the 3D printing process.
3.6. In Vitro Dissolution Study
3.6.1. Influence of the Composition of 3D Printed Controlled-Release Shells
Before performing the dissolution studies of the enclosed tablet, the sealing of the shell was
investigated. The tablet model was soaked with color dye (methylene blue) and enclosed inside the 3D
printed controlled-release shell. Then, the enclosed shell was placed in a 100-mL beaker filled with
distilled water. The visual observation of the gradual change of the color intensity of the water by the
methylene blue at a different time intervals (Figure 3) proves that there was no sudden leakage of the
tablet content from the shell, and that the release of methylene blue through the shell was controlled.
The in vitro dissolution study was carried out to determine the release of propranolol HCl from
the developed 3D printed shell and the encapsulated tablet. The dissolution study of the tablet model
revealed an immediate release profile of propranolol HCl, with >95% of the drug released within 20 min.
It was found that the release of propranolol HCl from the 3D printed shell showed controlled/sustained
release compared to the tablet model (Figure 4a). This result validates the proof of concept that the 3D
printing technique has potential applications in modifying the drug release profile of conventional
immediate-release tablets.
The composition of the controlled-release shells (shells A, B, and C), as shown in Table 3, influenced
the release profile of propranolol HCl (Figure 4a). Among the three different shell formulations, shell A
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exhibited 84% propranolol release while shell B and C allowed for 66% and 48% release of propranolol
HCl after 12 h, respectively. Figure 4b showed the intact shell after the 12-h dissolution time, and the
cross-section of the shell system showed the expansion of the disintegrated tablet inside the shell
without breaking it during the dissolution.
The alteration in release profiles of propranolol HCl was due to the variability in the amount
of rate-controlling polymer (cellulose acetate) and the pore-forming agent (D-mannitol) used in the
formulation composition. The results demonstrate that an increase in the amount of D-mannitol in the
shell composition led to an increase in drug release. This behaviour is correlated to the micropores formed
by the rapid dissolution of D-mannitol in the controlled-release shell, which ultimately enhances the water
intake, driven by the difference in the osmotic pressure across the shell. This facilitates faster dissolution
of the enclosed tablet compared to the shell composition with less D-mannitol. Khaled et al. also reported
the impact of variable amounts of cellulose acetate as a drug release retardant in their investigations [4,28].Polymers 2020, 12, x FOR PEER REVIEW 9 of 17 
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Figure 3. Illustration representing encapsulation of the propranolol HCl tablet soaked with color
dye (methylene blue) kept inside 3D printed controlled-release shell, with the gradual increase in the
intensity of the color solution showing the visual observation of methylene blue release through the 3D
printed controlled-release shell at different time intervals.
Table 3. Influence of different compositions of 3D printed controlled-release shell on % cumulative drug
release after 12 h with phosphate buffer (pH 6.8) as dissolution media at a temperature of 37 ± 0.5 ◦C.
Formulation % CompositionCellulose Acetate D–Mannitol PEG 6000
% Cumulative Drug
Release After 12 h
Shell A 20 65 15 84.64 ± 1.99
Shell B 40 45 15 66.60 ± 1.13
Shell C 60 25 15 48.37 ± 1.46
3.6.2. Influence of the Size of he 3D P inted C ntrolled-Releas Shell
The formulation of shell B had a balanced ratio between cellulose acetate and D-mannitol (Table 3).
Therefore, it was selected to assess further the influence of different sizes of 3D printed coating shells on
the cumulative release of the propranolol HCl. Three different-sized shells were printed (fixed, medium,
and l rge). The outer and inn r diamet r and the gap between the shell wall d the tablet are shown
in Table 4. The uncapped shell and the enclosed able of the thr e shell sizes are show in Figure 5a.
The in vitro dissolution work was carried out to evaluate the propranolol HCl release from the enclosed
tablet inside the three different shells varying in sizes (Figure 5b). The propranolol HCl release rate
was enhanced with respect to an increase in the size of the shell (Figure 5b).
Over a period of 12 h, 66.60%, 72.68%, and 76.81% of propranolol HCl was released from the tablet
enclosed in the fixed-, medium-, and large-sized shells, respectively (Table 4). As the space between
the shell wall and the tablet increased, so did the amount of dissolution medium that filled that space,
and consequently, there was more dissolved propranolol HCl from the enclosed tablet. The increase
in the shell size provided a larger area (space/gap between the shell wall and the enclosed tablet)
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available for the tablet to expand during the disintegration process, resulting in more dissolution and
drug release (Figure 5a,b). The concept of accommodating the space/gap between the enclosed tablet
and the shell wall demonstrated a novel idea, paving the way to explore a different approach and
hypothesis. The provided space/gap could be utilized for filling with release enhancers/solubilizers or
release retardant, and the drug release from the enclosed tablet might be customized as per desirability
into a delayed-release or time-dependent drug release system.
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Figure 4. (a) Cumulative release of propranolol HCl from the model tablet with phosphate buffer
(pH 6.8) as dissolution media at temperature 37 ± 0.5 ◦C versus when enclosed inside 3D printed
coating shells with different excipient ratios (Table 3). (b) The coating shell system still intact after the
dissolution experiment. The cross-section of the shell shows the expansion of the propranolol HCl
tablet inside the shell.
Table 4. Influence of different sizes of 3D printed controlled-release shells on cumulative drug release








The Gap between the
Shell Wall and Tablet
Fixed-sized shell 12 mm 9.6 mm 0.8 mm 66.60 ± 1.13
Medium-sized shell 13 mm 10.6 mm 1.3 mm 72.68 ± 2.34
Large-sized shell 14 mm 11.6 mm 1.8 mm 76.81 ± 1.60
3.6.3. Drug Release Kinetics
Kinetic modeling plays an essential role in determining the drug release mechanism [36,37].
The drug release data were fitted by using the zero-order, first order, Higuchi, and Korsmeyer–Peppas
models to investigate the best-fit model [36,38]. The results are shown in Table 5.
Polymers 2020, 12, 1395 12 of 16Polymers 2020, 12, x FOR PEER REVIEW 13 of 17 
 
 
Figure 5. (a) Different sizes of 3D printed controlled-release shells illustrating the gap/space between 
the enclosed tablet and the shell wall. (b) Cumulative release of propranolol HCl with phosphate 
buffer (pH 6.8) as dissolution media at temperature 37 ± 0.5 °C from 3D printed controlled-release 
shells of different sizes. 
3.6.3. Drug Release Kinetics 
Kinetic modeling plays an essential role in determining the drug release mechanism [36,37]. The 
drug release data were fitted by using the zero-order, first order, Higuchi, and Korsmeyer–Peppas 
models to investigate the best-fit model [36,38]. The results are shown in Table 5.  
Table 5. In vitro release kinetics of propranolol HCl from 3D printed controlled-release shells of 
variable composition and size fitted to the best-fit release kinetic model. 
Formulation Type Zero Order (r2) First Order (r2) Higuchi (r2) 
Korsmeyer–Peppas 
(r2) n Value 
Composition-based      
Formulation A 0.9521 0.9939 0.9906 0.9662 0.542 
Formulation B 0.9937 0.9741 0.9503 0.9954 0.619 
Formulation C 0.9817 0.9541 0.9106 0.9959 0.576 
Size-based       
Fixed-sized shell 0.9937 0.9741 0.9503 0.9954 0.619 
Medium-sized shell 0.9949 0.9622 0.9516 0.9964 0.621 
Large-sized shell 0.9902 0.9583 0.9583 0.9942 0.622 
Diffusion-based drug release can be either Fickian or non-Fickian [39]. In Fickian diffusion, the 
release rate is independent of the drug concentration in the dosage forms. The zero-order release 
kinetics model describes delivery systems where the drug release rate is constant with respect to time. 
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different sizes.
Table 5. In vitro release kinetics of propranolol HCl from 3D printed controlled-release shells of variable
composition and size fitted to the best-fit release kinetic model.




Formulation A 0.9521 0.9939 0.9906 0.9662 0.542
Formulation B 0.9937 0.9741 0.9503 0.9954 0.619
Formulation C 0.9817 0.9541 0.9106 0.9959 0.576
Size-based
Fixed-sized shell 0.9937 0.9741 0.9503 0.9954 0.619
Medium-sized shell 0.9949 0.9622 0.9516 0.9964 0.621
Large-sized shell 0.9902 0.9583 0.9583 0.9942 0.622
Diffusion-bas d drug release can be either Fickian or non-Fickian [39]. In Fickian diffusion, the release
rate is independent of the drug concentration in the dosage forms. The zero-order release kinetics model
describes delivery systems where the drug release rate is constant with respect to time. In non-Fickian
diffusion, several factors can affect the drug release, and based on these factors, the release can be
predicted by several mathematical models like the first-order release kinetics model, the Higuchi release
kinetics model, and the Korsmeyer–Peppas release kinetics model, etc. In first-order release kinetics,
the drug release rate is concentration-dependent. The Korsmeyer–Peppas release kinetic model relates
the drug release exponentially to the fractional release of the drug [40]. The equation can be written
as follows:
Qt/ Q∞ = ktn
where Qt/Q∞is a fraction of drug released at time t; k is the release rate constant; and n is the release exponent.
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The value of n can indicate likely mechanisms for drug release. For example, Ritger and Peppas
determined that n should be in the range of 0.425–0.500 for disk-shaped devices if the release profile
indicates that diffusion of dissolved drug through a matrix is the dominant release mechanism [41,42].
The n value of about 1.0 indicates that polymer relaxation, polymer dissolution, or tablet erosion is
the dominant mechanism. An intermediate value suggests a combination of mechanisms is effective,
involving the so-called non-Fickian diffusion, anomalous release, or mixed transport.
Among the shell compositions investigated, the release of propranolol HCl from shell A (containing 20%
cellulose acetate and 65% mannitol) was best fitted to first-order kinetics, with an R2 value of 0.9939,
showing that the release rate depends on its concentration. The release of propranolol HCl from shells
B and C (containing 40% and 60% cellulose acetate and 45% and 25% mannitol, respectively) was best
fitted to the Korsmeyer–Peppas model, with R2 values of 0.9954 and 0.9959, respectively. n-Values ranged
between 0.576 and 0.619, indicating a non-Fickian diffusion model of drug release.
Similarly, the release of propranolol HCl from the tablets enclosed in shells (the composition of
formulation B), including fixed-, medium- and large-sized shells, was best fitted to the Korsmeyer–Peppas
model, with R2 values of 0.9954, 0.9964, and 0.9942, respectively. Shell sizes with fixed-, medium-,
and large geometry showed n-values of 0.619, 0.621, and 0.622, respectively. This indicates a non-Fickian
diffusion model of drug release. Among the three geometries, the fixed size was more compact; therefore,
less area was available for exposure to the dissolution media and hence the release rate was lower
compared to drug release from the medium and the large shell. In contrast, the medium and large sizes
of the shell provided more area for exposure to the dissolution media, leading to faster disintegration of
the tablet and thus an improved release rate of propranolol HCl.
The current approach shows that the modulation of the shell formulation and size represents an
opportunity to control the amount and rate of propranolol HCl released from the off-the-shelf tablet.
This novel idea can be developed further and applied to encapsulate the available conventional dosage
forms to fulfil the needs of personalized medicine. This new perspective on the use of 3D printing
could be applied to customize the amount and release profile of the enclosed available conventional
drug tablet instead of developing a 3D printing model for each drug.
Promising dosage forms with modified-release profiles as per desirability have been fabricated
using 3D printing technology [6]. However, the content verification, the formulation supply of each
drug, and the expected competition between the conventional and the 3D printed dosage forms of the
same drug are among the various difficulties found in the application of 3D printing in the healthcare
system [8]. Here, we suggest that the encapsulation of conventional immediate-release tablets using
3D printed coating shells will bridge the gap between the currently available conventional tableting
methods and the future applications of 3D printing technology to meet the final goal, which is to
provide effective treatment with minimum adverse effects.
4. Conclusions
The fabrication of an encapsulating shell using extrusion-based 3D printing at room temperature
showed no significant impact on the physicochemical character of the materials used to design the
encapsulating system. This method provided the ability to use pharmaceutical grade excipients in
different ratios without affecting the quality of the printed product. The use of different ratios of
cellulose acetate to D-mannitol for the fabrication of the encapsulating shell showed the ability to control
the amount and the rate of propranolol HCl released from off-the-shelf tablet (Indicardin®). Further,
the dissolution profile of the 3D printed controlled-release shell of different sizes also influenced the
release of propranolol HCl, in which the combination of material composition and shell size allowed
for a fine-tuning of the release profile. This approach could be explored further to help healthcare
professionals customize the drug amount and the release profile of the available conventional tablets
to provide the greatest therapeutic efficacy with the minimum untoward effects commonly associated
with the administration of the immediate-release tablets.
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